UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 121, 2021

VIELA BIO, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-39067	82-4187338
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
One Medimmune Way, First Floor, Area Two Gaithersburg, Maryland		20878
(Address of principal executive offices)		(zip code)


One Medimmune Way, First Floor, Area Two
Gaithersburg, Maryland		20878
(Address of principal executive offices)		(zip code)

Registrant’s telephone number, including area code: (240) 558-0038

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	VIE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial ~~Conditions~~Condition.

On March 1, 2021, Viela Bio, Inc. (the “Company”) isissued ~~providing~~a ~~certain~~press ~~preliminary~~release ~~(unaudited)~~announcing ~~consolidated~~its financial ~~information~~results for ~~its~~the ~~fiscal~~fourth ~~year~~quarter ~~ended December 31, 2020. Based on preliminary unaudited information~~ and ~~management~~full ~~estimates for the fiscal~~ year ended December 31, 2020, and ~~subject~~providing tobusiness ~~the~~highlights. The ~~completion~~full text of the ~~Company’s~~press ~~financial~~release ~~closing~~is ~~procedures,~~furnished ~~the~~as ~~Company~~Exhibit ~~currently estimates~~99.1 ~~its~~to ~~cash,~~this ~~cash~~Current ~~equivalents~~Report ~~and~~on ~~marketable~~Form ~~securities as of December 31, 2020 to be approximately $380 million~~8-K.

The ~~Company’s estimate~~information ~~of its consolidated cash, cash equivalents and marketable securities as of December 31, 2020 has been prepared by management~~ in ~~good~~this ~~faith~~Current ~~based~~Report ~~upon~~on ~~internal~~Form ~~reporting~~8-K ~~and~~(including ~~expectations~~Exhibit 99.1) ~~However,~~shall ~~because the Company’s financial closing procedures for the fourth quarter and fiscal year ended December 31, 2020 have~~ not ~~been~~be ~~completed,~~deemed ~~this estimate is preliminary, is subject~~ to ~~change and may~~ be “filed” ~~revised~~for aspurposes ~~a result~~ of ~~management’s~~Section 18 ~~further review~~ of ~~its~~the ~~consolidated financial~~Securities ~~position~~Exchange asAct of ~~December 31~~1934, ~~2020~~as ~~and~~amended ~~its consolidated financial results for~~ (the ~~fourth~~“Exchange ~~quarter and fiscal year ended December 31~~Act”), ~~2020.~~or Asotherwise asubject ~~result,~~to ~~there~~the ~~can~~liabilities beof ~~no assurance~~ that ~~the~~section, ~~final~~nor ~~results~~shall ~~for~~it ~~this period will not differ materially from this estimate. The above information should not~~ be ~~viewed~~deemed asincorporated aby ~~substitute~~reference ~~for full consolidated financial statements prepared~~ in ~~accordance~~any filing ~~with~~under ~~generally accepted accounting principles. In addition,~~ the ~~above~~Securities ~~information~~Act ~~is not necessarily indicative~~ of ~~the~~1933, ~~Company’s consolidated financial position~~ as ~~of any future date and is subject to risks and uncertainties~~amended, ~~many~~or ~~of which are not within~~ the ~~Company’s~~Exchange ~~control.~~Act, ~~The~~except ~~above~~as ~~information~~expressly ~~should~~set beforth ~~read~~by ~~together~~specific ~~with the~~reference ~~Company’s consolidated financial statements and notes to those consolidated financial statements and the other information~~ in ~~the~~such ~~Company’s~~a ~~Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Reports on Form 10-Q for the periods ended March 31, 2020, June 30, 2020 and September 30, 2020~~filing.

~~SIGNATURES~~Item 9.01 Financial Statements and Exhibits.

~~Pursuant~~(d) toExhibits ~~the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~

VIELA BIO, INC. By: /s/ Mitchell Chan Mitchell Chan Chief Financial Officer


Exhibit No.		Description

99.1		Press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2020, dated March 1, 2021.

~~Date: February~~SIGNATURES ~~16, 2021~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


VIELA BIO, INC.

By:		/s/ Mitchell Chan
		Mitchell Chan
		Chief Financial Officer

Date: March 1, 2021

Filing Compare · Viela Bio, Inc.